Life expectancy for individuals diagnosed with ROS1-positive non-small cell lung cancer varies widely depending on the stage at diagnosis, overall health, and treatment response, but modern targeted tyrosine kinase inhibitors have extended median overall survival well beyond historical benchmarks. Many patients receiving advanced targeted therapies experience progression-free survival timelines spanning several years, turning the diagnosis into a manageable chronic condition.